Back
SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
E-Poster
https://storage.unitedwebnetwork.com/files/1099/c163655b1e981a04459efec4df75ffdc.pdf
Abstract Title
SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
First Name *
Jonathan
Last Name *
Barratt
Co-author 1
Brad Rovin
brad.rovin@osumc.edu
Ohio State University Wexner Medical Center
Division of Nephrology
Columbus
Co-author 2
Edward Murphy
edward.murphy@travere.com
Travere Therapeutics, Inc.
Biostatistics
San Diego
Co-author 3
Radko Komers
radko.komers@travere.com
Travere Therapeutics, Inc.
Clinical Development, Nephrology
San Diego
Co-author 4
Hernán Trimarchi
htrimarchi@hotmail.com
British Hospital of Buenos Aires
Nephrology Service
Buenos Aires
Co-author 5
Vlado Perkovic
vlado.perkovic@unsw.edu.au
University of New South Wales Sydney
Faculty of Medicine & Health
Sydney
E-Poster Format Requirements
PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but
must be saved and submitted as PDF file
.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos